Avoidance of Bias in Clinical Trials

Avoidance of Bias in Clinical Trials describes the systematic implementation of trial design features, operational procedures, and statistical analyses preventing systematic errors that could lead to incorrect conclusions about therapeutic efficacy or safety, ensuring that trial results accurately reflect the true effects of investigational treatments.

The pharmaceutical industry implements multiple bias prevention strategies in clinical trial design and execution. Randomisation eliminates selection bias distributing prognostic factors equally across treatment arms. Blinding prevents measurement bias from knowledge of treatment assignments affecting outcome assessment. Allocation concealment prevents investigators from predicting future assignments. Pre-specified statistical analysis plans prevent post-hoc data fishing. Independent data monitoring committees provide unbiased interim safety and efficacy oversight. Intention-to-treat analyses preserve randomisation benefits despite protocol deviations. Regulatory agencies critically evaluate bias risks in trial designs, requiring adequate justification for any unblinded or non-randomised elements. As decentralised trials introduce new bias risks through heterogeneous assessment environments, bias avoidance strategies continue evolving addressing novel trial designs.